ArticleBMC cancer2013
Survival of patients with operable breast cancer (Stages I-III) at a Brazilian public hospital--a closer look into cause-specific mortality.
Article in BMC cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen.BMC cancer · 2016Trial
- Social inequalities in survival among women with breast cancer in southeastern Brazil: a retrospective cohort study.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Article
- Breast Cancer Heterogeneity in Latin America: A Scoping Review of Clinical-Pathological Characteristics, Molecular Subtypes, and Survival.World journal of surgery · 2025Article
- Changes in Invasive Breast Carcinomas after Neoadjuvant Chemotherapy Can Influence Adjuvant Therapeutic Decisions.Cancer research and treatment · 2024Article
- Ten-Year Survival of Breast Cancer in Iran: A National Study (Retrospective Cohort Study).Breast care (Basel, Switzerland) · 2023Article
- Breast cancer survival and the health system in Brazil: an analysis of public and private healthcare.Frontiers in oncology · 2023Article
- Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast Brazil.The oncologist · 2022Article
- Five-year survival rate and prognostic factors in women with breast cancer treated at a reference hospital in the Brazilian Amazon.PloS one · 2022Article
- Survival of south african women with breast cancer receiving anti-retroviral therapy for HIV.Breast (Edinburgh, Scotland) · 2021Article
- Article
- Modeling risk assessment for breast cancer in symptomatic women: a Saudi Arabian study.Cancer management and research · 2019Article
- 5-Year Survival Rates and Prognostic Factors in Patients with Synchronus and Metachronus Breast Cancer from 2010 to 2015Asian Pacific journal of cancer prevention : APJCP · 2018Article
- Outcome of Patients With Breast Cancer Treated in a Private Health Care Institution in Brazil.Journal of global oncology · 2018Article
- Patient Navigation to Improve Access to Breast Cancer Care in Brazil.Journal of global oncology · 2017Article
- Accuracy of a probabilistic record-linkage methodology used to track blood donors in the Mortality Information System database.Cadernos de saude publica · 2014Article
- Factors related to survival rates for breast cancer patients.International journal of clinical and experimental medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer incidence is increasing. The survival rate varies and is longer in high-income countries. In Brazil, lower-income populations rely on the Unified Public Health System (Sistema Único de Saude, SUS) for breast cancer care. The goal of our study is to evaluate the survival of patients with operable breast cancer stages I-III at a Brazilian public hospital that treats mostly patients from the SUS.
methodsA cohort study of patients who underwent surgery for breast cancer treatment at the Clinical Hospital of the Federal University of Minas Gerais from 2001 to 2008 was performed, with a population of 897 cases. Information on tumor pathology and staging, as well as patients' age and type of health coverage (SUS or private system) was collected. A probabilistic record linkage was performed with the database of the Mortality Information System to identify patients who died by December 31th, 2011. The basic cause of death was retrieved, and breast cancer-specific survival rates were estimated with the Kaplan-Meier method. The Cox proportional hazards model was used for univariate and multivariate analysis of factors related to survival.
resultsA total of 282 deaths occurred during the study's period, 228 of them due to breast cancer. Five-year breast cancer-specific survival rates were 95.5% for stage I, 85.1% for stage II and 62.1% for stage III disease. Patients from the SUS had higher stages at diagnosis (42% was in stage III, and from the private system only 17.6% was in this stage), and in the univariate but not multivariate analysis, being treated by the SUS was associated with shorter survival (hazard ratio, HR = 2.22, 95% CI 1.24-3.98). In the multivariate analysis, larger tumor size, higher histologic grade, higher number of positive nodes and age older than 70 years were associated with a shorter breast cancer-specific survival.
conclusionsFive-year breast cancer survival was comparable to other Brazilian cohorts. Patients treated by the SUS, rather than by the private system, had shorter survival times, mostly due to higher initial stage of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.